NCT02534753View on ClinicalTrials.gov

A Pharmacokinetics Study of Intravenous Ascorbic Acid

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

January 31, 2016

Conditions
Pharmacokinetics
Interventions
DRUG

Ascor L 500® (Ascorbic Acid Injection, USP)

A sterile, solution containing 500 mg ascorbic acid per mL

Trial Locations (1)

23284

Virginia Commonwealth University, Richmond

Sponsors
All Listed Sponsors
lead

McGuff Pharmaceuticals, Inc.

INDUSTRY

NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid | Biotech Hunter | Biotech Hunter